関連する実験動画
Updated: Jun 7, 2026
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
バクテリアの酵素を阻害することによって,がん薬の毒性を軽減する
Bret D Wallace1, Hongwei Wang, Kimberly T Lane
1Department of Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA.
Science (New York, N.Y.)
|November 6, 2010
まとめ
研究者らは,大腸がん薬CPT-11による重度の下痢を引き起こす細菌酵素の標的型阻害剤を開発した. これらの阻害剤は,腸内微生物を保護し,マウスの薬物毒性を軽減し,がん治療の新たな戦略を提供します.
科学分野:
- 微生物学 微生物学とは
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- 重度の下痢は,一般的な結腸がん化学療法薬であるCPT-11の投与量を制限する副作用です.
- この毒性は,細菌のβ-グルキュロニダゼが腸内でのCPT-11を再活性化することによって引き起こされます.
- これらの細菌酵素を選択的に標的にすることで,有益な腸内細菌に害を与えることなく,毒性を軽減することができます.
研究 の 目的:
- バクテリア β-グルキュロニダゼの有力かつ選択的阻害剤を特定する.
- これらの阻害剤の細菌酵素に対する有効性を in vitro および in vivo で評価する.
- CPT-11による毒性の予防におけるこれらの阻害剤の治療の可能性を評価する.
主な方法:
- バクテリア β-グルキュロニダース阻害剤を特定するための高通量スクリーニング.
- 酵素検査は,細菌や哺乳類のオートロジに対する阻害剤の効能と選択性を決定する.
- 選択性の基礎を理解するための結晶構造分析.
- 生体有酸素および無酸素細菌および哺乳類の細胞で阻害剤を試験する.
- CPT-11の毒性に対する保護を評価するためにマウスでのin vivo研究.
主要な成果:
- 強力な細菌 β-グルキュロニダース阻害剤が特定されました.
- 阻害剤は,独特の構造的特徴に基づいて,哺乳類のオルトログよりも細菌酵素に高い選択性を示しました.
- 阻害剤は,細菌の標的酵素に対して,細菌の死亡を引き起こさず,哺乳類の細胞を傷つけることなく有効でした.
- 阻害剤の経口投与は,CPT-11-誘発性下痢からマウスを成功裏に保護しました.
結論:
- 微生物酵素の選択的抑制は,化学療法の有効性を高めるための有効な戦略です.
- このアプローチは,特定の微生物の活動をターゲットにすることで,薬物による毒性を軽減することができます.
- このような標的型阻害剤の開発は,がん患者のアウトカムを改善するための有望な道を提供します.
関連する概念動画
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...